Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight

Description:

The "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available in India, Japan, Kenya, Czech Republic, Estonia, Germany, China, Slovakia, United Kingdom for the treatment of Type 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014.

Lantus is the brand name for Insulin Glargine, a man made form of hormone generally produced in the human body, used in the treatment of diabetes mellitus in children and adults. The long lasting process of insulin works to lower down the levels of glucose (sugar) in blood. Lantus is also used to treat type 2 & type 1 diabetes in adults and children having more than 6 years of age. The drug usually starts working after several hours of injection and keeps performing for 18-26 hours or more without any pronounced peak.

Lantus is a package consisting of a sterile solution of insulin glargine containing zinc, m-cresol, glycerol 85%, polysorbate and water for injection as inactive ingredients. Each milliliter of Lantus contains 100 Units (3.6378mg) of insulin glargine. The pH of Lantus is adjusted by addition of hydrochloric acid and sodium hydroxide. It has a pH value of approximately 4 making it completely soluble. It is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) acting as production organism. Chemical representation of insulin glargine present in Lantus is 21A-Gly-30Ba-L-Arg-3030b-L-Arg-human insulin and empirical formula as C267H404N72O78S6 and a molecular weight of 6063.

The key function of Lantus consisting insulin is to regulate blood sugar levels is performed by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production. Lantus consists of a substitution of glycine as asparagine at N21 combining with 2 additional arginines to the carboxy terminal of B chain. The arginine amino acids are responsible for shifting the isoelectric point to 5.4 to 6.7, making the molecule more soluble in acidic pH and less soluble in physiological pH. This shift allows a subcutaneous injection of a clear solution.

Lantus treatment demands for daily dosage as injection under the skin into the subcutaneous tissue and not intravenously or by using insulin pumps. The injection is to be taken once in day time followed by 1 injection each day at the same time. The dosage is adjusted according to individual's physical activity, severe conditions of illness and changes in food intake. It is injected into abdominal area, thigh and deltoid. The place to inject can be replaced within the region to reduce the risk of side effects.

Contents:

1. Lantus (Insulin glargine) Clinical Insight
   1.1 Clinical Introduction
   1.2 Patent Analysis by Indication
   1.3 Phase of Development
   1.4 Brand Names by Country/Region

Lantus Biosimilars Clinical Insight by Company

2. Insulin Glargine (Insulin U300)
   2.1 Clinical Insight
   2.2 Development Timeline
   2.3 Patent Analysis
   2.4 Phase of Development

3. Insulin Glargine - HEC Pharm
   3.1 Clinical Insight
   3.2 Phase of Development

4. Insulin Glargine Biosimilar - Biocon/Mylan
   4.1 Clinical Insight
   4.2 Development Timeline
   4.3 Phase of Development
5. Insulin Glargine Biosimilar - Boehringer Ingelheim/Eli Lilly
5.1 Clinical Insight
5.2 Development Timeline
5.3 Patent Analysis
5.4 Phase of Development

6. Insulin Glargine Biosimilar - Gan & Lee Pharmaceuticals
6.1 Clinical Insight
6.2 Development Timeline
6.3 Phase of Development

7. Insulin Glargine Biosimilar - GEROPHARM
7.1 Clinical Insight
7.2 Phase of Development

8. Insulin Glargine Biosimilar - Harvest Moon Pharmaceuticals
8.1 Clinical Insight
8.2 Phase of Development

9. Insulin Glargine Biosimilar - LG Life Sciences
9.1 Clinical Insight
9.2 Phase of Development

10. Insulin Glargine Biosimilar - Paras Biopharmaceuticals
10.1 Clinical Insight
10.2 Patent Analysis
10.3 Phase of Development

11. Insulin Glargine Biosimilar - Samsung Bioepis/Merck & Co.
11.1 Clinical Insight
11.2 Development Timeline
11.3 Patent Analysis
11.4 Phase of Development

12. Insulin Glargine Biosimilar - Wockhardt
12.1 Clinical Insight
12.2 Development Timeline
12.3 Phase of Development

13. Recombinant Insulin Glargine Biosimilar - Biogenomics
13.1 Clinical Insight
13.2 Phase of Development

List of Tables:
Table 2-1: Insulin U300 Insulin Glargine by Indication & Phase
Table 3-1: HEC Pharm Insulin Glargine by Indication & Phase
Table 4-1: Biocon/Mylan Insulin Glargine Biosimilar by Indication & Phase
Table 5-1: Boehringer Ingelheim/Eli Lilly Insulin Glargine Biosimilar by Indication & Phase
Table 6-1: Gan & Lee Pharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
Table 7-1: GEROPHARM Insulin Glargine Biosimilar by Indication & Phase
Table 8-1: Harvest Moon Pharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
Table 9-1: LG Life Sciences Insulin Glargine Biosimilar by Indication & Phase
Table 10-1: Paras Biopharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
Table 11-1: Samsung Bioepis/Merck & Co. Insulin Glargine Biosimilar by Indication & Phase
Table 12-1: Wockhardt Insulin Glargine Biosimilar by Indication & Phase
Table 13-1: Biogenomics Recombinant Insulin Glargine Biosimilar by Indication & Phase

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3927854/](http://www.researchandmarkets.com/reports/3927854/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight
Web Address: http://www.researchandmarkets.com/reports/3927854/
Office Code: SC2GKERI

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 1500 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 1500 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 2000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World